Striatal dopamine- and glutamate-mediated dysregulation in experimental parkinsonism

Trends in Neurosciences

Volumn 23, Issue 10 SUPPL., 2000, Pages

  Chase, Thomas N ^a   Oh, Justin D ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPA RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

4 AMINOBUTYRIC ACID BRAIN LEVEL; CORPUS STRIATUM; DOPAMINE BRAIN LEVEL; HUMAN; PARKINSONISM; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW; TARGET CELL;

EID: 0033677879     PISSN: 01662236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1471-1931(00)00018-5     Document Type: Review

References (85)

1. Problems with long-term levodopa therapy for Parkinson's disease
2. Motor complications of chronic levodopa therapy in Parkinson's disease
3. Palliative and prophylactic benefits of continuously administered dopaminomimetics in Parkinson's disease
4. Apomorphine responses in Parkinson's disease and the pathogenesis of motor complications
5. Striatal mechanisms and pathogenesis of parkinsonian signs and motor complications
6. Postsynaptic integration of glutamatergic and dopaminergic signals in the striatum
7. The organization of the projection from the cerebral cortex to the striatum in the rat
8. Corticostriatal innervation of the patch and matrix in the rat striatum
9. The control of firing pattern in nigral dopamine neurons: Single spike firing
10. Behavior-related activity of primate dopamine neurons
11. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations
12. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications
13. L-dopa in Parkinsonism. A possible mechanism of action
14. Nonaminergic striatal neurons convert exogenous L-dopa to dopamine in parkinsonism
15. L-3,4-dihydroxyphenylalanine-induced dopamine release in the striatum of intact and 6-hydroxydopamine-treated rats: Differential effects of monoamine oxidase A and B inhibitors
16. The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments
17. Levodopa replacement therapy alters enzyme activities in striatum and neuropeptide content in striatal output regions of 6-hydroxydopamine lesioned rats
18. Continuous and intennittent levodopa differentially affect basal ganglia function
19. Motor fluctuations in levodopa treated parkinsonian rats: Relation to lesion extent and treatment duration
20. Effects of L-DOPA on preproenkephalin and preprotachykinin gene expression in the MPTP-treated monkey striatum
21. Effects of kappa receptor agonists on D1 and D2 dopamine agonist and antagonist-induced behaviors
22. NMDA receptor blockade reverses motor response alterations induced by levodopa
23. Reversal of levodopa-induced motor fluctuations in experimental parkinsonism by NMDA receptor blockade
24. MK801 prevents levodopa-induced motor response alterations in parkinsonian rats
25. Levodopa-induced dyskinesia and response fluctuations in primates rendered parkinsonian with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)
26. Effect of nondopaminergic drugs on L-dopa-induced dyskinesias in MPTP-treated monkeys
27. Levodopa-induced dyskinesias improved by a glutamate antagonist in Parkinsonian monkeys
28. Amantadine reduces levodopa-induced dyskinesias in parkinsonian monkeys
29. Differing effects of N-methyl-D-aspartate receptor subtype selective antagonists on dyskinesias in levodopa treated 1-methyl-4-phenyl-tetrahydropyridine monkeys
30. Aminoadamantanes as NMDA receptor antagonists and antiparkinsonian agents-preclinical studies
31. Acute pharmacologic blockade of dyskinesias in Parkinson's disease
32. Dextromethorphan improves levodopa-induced dyskinesias in Parkinson's disease
33. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease
34. Physiological and molecular properties of AMPA/kainate receptors expressed by striatal medium spiny neurons
35. Non-NMDA receptor mediated mechanisms are involved in levodopa-induced motor response alterations in parkinsonian rats
36. AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys
37. Metabotropic glutamate receptor mRNA expression in the basal ganglia of the rat
38. Metabotropic glutamate receptor activation produces extrapyramidal motor system activation that is mediated by striatal dopamine
39. The role of nigrostriatal dopamine in metabotropic glutamate agonist-induced rotation
40. NMDA receptor subunits in the postsynaptic density of rat brain: Expression and phosphorylation by endogenous protein kinases
41. Modification of glutamate receptor channels: Molecular mechanisms and functional consequences
42. Regulation of NMDA receptors by tyrosine kinases and phosphatases
43. NMDA channel regulation by channel-associated protein tyrosine kinase Src
44. Phosphorylation-dependent regulation of N-methyl-D-aspartate receptors by calmodulin
45. Characterization of protein kinase A and protein kinase C phosphorylation of the N-methyl-D-aspartate receptor NR1 subunit using phosphorylation site-specific antibodies
46. Tyrosine phosphorylation of NMDA receptor in rat striatum: Effects of 6-OH-dopamine lesions
47. Enhanced tyrosine phosphorylation of striatal NMDA receptor subunits: Effect of dopaminergic denervation and levodopa administration
48. Dopaminergic denervation of striatum results in elevated expression of NR2A subunit
49. Effect of dopamine denervation and dopamine agonist administration on serine phosphorylation of striatal NMDA receptor subunits
50. Alterations in subunit expression, composition and phosphorylation of striatal N-methyl-D-aspartate glutamate receptors in a rat 6-hydroxydopamine model of Parkinson's disease
51. Ultrastructural localalization of D2 receptor-like immunoreactivity in midbrain dopamine neurons and their striatal targets
52. Protein kinase A inhibitor attenuates levodopa-induced motor response alterations in the hemiparkinsonian rat
53. NMDA receptor subunits epsilon 1 (NR2A) and epsilon 2 (NR2B) are substrates for Fyn in the postsynaptic density fraction isolated from the rat brain
54. The activation of calcium/calmodulin-dependent protein-kinase II after glutamate or potassium stimulation in hippocampal slices
55. Modification of central dopaminergic mechanisms by continuous levodopa therapy for advanced Parkinson's disease
56. Memory formation: The sequence of biochemical events in the hippocampus and its connection to activity in other brain structures
57. Long-term potentiation at excitatory amino acid synapses on midbrain dopamine neurons
58. Levodopa-induced dyskinesia: A pathological form of striatal synaptic plasticity?
59. LTP, NMDA, genes and learning
60. Postsynaptic protein phosphorylation and LTP
61. Toward a molecular definition of long-term memory storage
62. Effects of single and multiple treatments with L-dihydroxyphenylalanine (L-DOPA) on dopamine receptor-G protein interactions and supersensitive immediate early gene responses in striata of rats after reserpine treatment or with unilateral nigrostriatal lesions
63. Network-level changes in expression of inducible fos-jun proteins in the striatum during chronic cocaine treatment and withdrawal
64. Enhanced CREB phosphorylation and changes in c-FOS and FRA expression in striatum accompany amphetamine sensitization
65. L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA
66. Changes in the regional and compartmental distribution of FosB- and JunB-like immunoreactivity induced in the dopamine-denervated rat striatum by acute or chronic L-dopa treatment
67. Preproenkephalin mRNA expression in the caudate-putamen of MPTP monkeys after chronic treatment with the D2 agonist U91356A in continuous or intermittent mode of administration: Comparison with L-DOPA therapy
68. Time dependence and role of N-methyl-D-aspartate glutamate receptors in the priming of D2-mediated rotational behavior and striatal Fos expression in 6-hydroxydopamine lesioned rats
69. CREB1 encodes a nuclear activator, a repressor, and a cytoplasmic modulator that form a regulatory unit critical for long-term facilitation
70. Regulation of CBP-mediated transcription by neuronal calcium signaling
71. Multiple splice patterns of cyclic AMP response element-binding protein mRNA in the central nervous system of the rat
72. Cyclic AMP stimulates somatostatin gene transcription by phosphorylation of CREB at serine 133
73. 2+ regulated transcription factor phosphorylated by calmodulin-dependent kinase
74. NMDA and D1 receptors regulate the phosphorylation of CREB and the induction of c-fos in striatal neurons in primary culture
75. Calcium-stimulated adenylyl cyclase activity is critical for hippocampus-dependent long-term memory and late phase LTP
76. The Ca-calmodulin-dependent protein kinase cascade
77. Positive and negative regulatory mechanisms that mediate long-term memory storage
78. Stimulation of cAMP response element (CRE)-mediated transcription during contextual learning
79. CREB and memory
80. Levodopa therapy: Consequences of the nonphysiologic replacement of dopamine
81. Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. The PKDS009 Study Group
82. Adenosine A2A antagonist: A novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys
83. Antiparkinsonian effect of a new selective adenosine A2A receptor antagonist in MPTP-treated monkeys
84. Kappa-opioid receptor agonists increase locomotor activity in the monoamine-depleted rat model of parkinsonism
85. Noradrenoceptor antagonism with idazoxan improves L-dopa-induced dyskinesias in MPTP monkeys